Metastatic Castration Resistant Prostate Cancer

Also known as: Metastatic Castration-Resistant Prostate Cancer / Metastatic castration resistant Prostate cancer

DrugDrug NameDrug Description
DB05812AbirateroneAbiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
DB08899EnzalutamideEnzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.
DB00635PrednisoneA synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
DrugDrug NamePhaseStatusCount
DB05812Abiraterone1Active Not Recruiting1
DB05812Abiraterone1Recruiting1
DB11901Apalutamide1Active Not Recruiting1
DB11595Atezolizumab1Recruiting1
DB15140Bempegaldesleukin1Not Yet Recruiting1
DB06772Cabazitaxel1Completed1
DB00002Cetuximab1Recruiting1
DB01248Docetaxel1Recruiting2
DB08899Enzalutamide1Recruiting2
DB01204Mitoxantrone1Completed1
DB09035Nivolumab1Not Yet Recruiting1
DB09035Nivolumab1Recruiting1
DB09074Olaparib1Recruiting1
DB00019Pegfilgrastim1Completed1
DB09037Pembrolizumab1Recruiting2
DB00635Prednisone1Active Not Recruiting1
DB00635Prednisone1Completed1
DB00635Prednisone1Recruiting1
DB05812Abiraterone1 / 2Recruiting1
DB14707Cemiplimab1 / 2Not Yet Recruiting1
DB05094Enzalutamide1 / 2Active Not Recruiting1
DB08899Enzalutamide1 / 2Active Not Recruiting1
DB08899Enzalutamide1 / 2Recruiting2
DB09037Pembrolizumab1 / 2Not Yet Recruiting1
DB05812Abiraterone2Active Not Recruiting2
DB05812Abiraterone2Completed1
DB05812Abiraterone2Recruiting2
DB00787Acyclovir2Completed1
DB11901Apalutamide2Recruiting1
DB11945Avelumab2Recruiting1
DB06772Cabazitaxel2Completed1
DB08889Carfilzomib2Completed1
DB01234Dexamethasone2Completed1
DB01248Docetaxel2Recruiting1
DB08899Enzalutamide2Active Not Recruiting2
DB05094Enzalutamide2Completed1
DB08899Enzalutamide2Completed1
DB08899Enzalutamide2Recruiting1
DB05094Enzalutamide2Withdrawn1
DB08899Enzalutamide2Withdrawn1
DB06186Ipilimumab2Recruiting1
DB09035Nivolumab2Recruiting1
DB09074Olaparib2Active Not Recruiting1
DB15110Onvansertib2Recruiting1
DB09037Pembrolizumab2Active Not Recruiting1
DB00635Prednisone2Completed1
DB00635Prednisone2Recruiting2
DB12813Radium Ra-2232Recruiting1
DB12332Rucaparib2Recruiting1
DB11836Sapanisertib2Completed1
DB05812Abiraterone3Active Not Recruiting2
DB05812Abiraterone3Recruiting1
DB06772Cabazitaxel3Active Not Recruiting1
DB01248Docetaxel3Active Not Recruiting2
DB08899Enzalutamide3Active Not Recruiting2
DB09074Olaparib3Active Not Recruiting1
DB09074Olaparib3Recruiting1
DB00860Prednisolone3Active Not Recruiting1
DB00635Prednisone3Active Not Recruiting1
DB12332Rucaparib3Recruiting1
DB05812Abiraterone4Completed1
DB00356Chlorzoxazone4Recruiting1
DB05094Enzalutamide4Completed1
DB08899Enzalutamide4Completed1
DB08899Enzalutamide4Recruiting1
DB08899Enzalutamide4Terminated1
DB00860Prednisolone4Completed1
DB01248DocetaxelNot AvailableCompleted1
DB05094EnzalutamideNot AvailableApproved for Marketing1
DB08899EnzalutamideNot AvailableApproved for Marketing1
DB08899EnzalutamideNot AvailableCompleted2
DB08913Radium Ra 223 DichlorideNot AvailableActive Not Recruiting1
DB09566Radium Ra 223 DichlorideNot AvailableActive Not Recruiting1
DB01268SunitinibNot AvailableCompleted1